| Overview |
| bs-11318R-PE-Cy3 |
| Ataxin 7 Polyclonal Antibody, PE-Cy3 Conjugated |
| WB |
| Mouse, Rat |
| Human, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| PE-Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Ataxin 7 |
| 301-400/892 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Nucleus |
| Ataxin7; Ataxin-7; ADCAII; ATXN 7; OPCA III; OPCA3; SCA 7; SCA7; Spinocerebellar Ataxia 7; Spinocerebellar ataxia type 7 protein; ATX7_HUMAN. |
| The human ataxin-7 gene, also known as spinocerebellar ataxia 7 or SCA7, maps to chromosome 3p13-p12, has a 2,727-bp open reading frame, and encodes a 892 amino acid protein containing a nuclear localization signal and a polyglutamine tract (1,2). SCA7 is an autosomal dominant neurodegenerative disorder characterized by ataxia and selective neuronal cell loss caused by the expansion of a translated CAG repeat encoding a polyglutamine tract in ataxin-7, which is the SCA7 gene product (3,4). Ataxin-7 is expressed within neurons both affected and unaffected in SCA7 pathology with subcellular localization being variable depending upon the neuronal subtype (5). Polyglutamine expanded in ataxin-7 may carry out its pathogenic effects in the nucleus by altering the matrix-associated nuclear structure and/or by disrupting nucleolar function (6). |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz